Providence Therapeutics Pipeline
Cutting Edge mRNA Pipeline in Infectious Diseases & Oncology
| mRNA Vaccine Approach | Program | Discovery | Proof-of-Concept | Pre-IND | Phase 1 | Phase 2 | Phase 3 | Partners |
|---|
 Oncology | |||
|---|---|---|---|
| Precision Medicine | PTX-102 | Solid Tumors – Precision Antigens |
 |
| PTX-103 | Glioblastoma – Common Antigens |
||
| Universal Cancer Vaccine | PTX-105 | Solid Tumors – Target Undisclosed |
Undisclosed |
 Infectious Diseases | |||
|---|---|---|---|
| Booster Vaccine | PTX-COVID19-B | COVID-19 – Spike – Phase 2 Results Published |
Program Paused |
| Post Exposure Vaccine | PTX-203 | Shingles |
|
| Prophylactic Vaccine | PTX-201 | Pan-Sarbecovirus– Multiantigen |
|
| PTX-205 | Highly Pathogenic Influenza |
||
| PTX-204 | Malaria – Multiantigen |
 |
|
| PTX-206 | Salmonella - Multiantigen |
 |
|
 Animal Health | |||
|---|---|---|---|
| Prophylactic Vaccine | PTX-301 | Highly Pathogenic Influenza |
Undisclosed |